• Something wrong with this record ?

New potent N-hydroxycinnamamide-based histone deacetylase inhibitors suppress proliferation and trigger apoptosis in THP-1 leukaemia cells

M. Onuscakova, T. Kauerova, E. Fialova, H. Pizova, V. Garaj, M. Kemka, V. Frecer, P. Kollar, P. Bobal

. 2025 ; 358 (4) : e2400889. [pub] -

Language English Country Germany

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25016225

Grant support
MEYS CR infrastructure project LM2023042
Masaryk University MUNI/A/1598/2020

A new group of potent histone deacetylase inhibitors (HDACis) capable of inhibiting cell growth and affecting cell-cycle progression in Tohoku Hospital Pediatrics-1 (THP-1) monocytic leukaemia cells was synthesized. The inhibitors belong to a series of hydroxamic acid derivatives. We designed and synthesized a series of 22 N-hydroxycinnamamide derivatives, out of which 20 are new compounds. These compounds contain various substituted anilides as the surface recognition moiety (SRM), a p-hydroxycinnamate linker, and hydroxamic acids as the zinc-binding group (ZBG). The whole series of synthesized hydroxamic acids inhibited THP-1 cell proliferation. Compounds 7d and 7p, which belong to the category of derivatives with the most potent antiproliferative properties, exert a similar effect on cell-cycle progression as vorinostat and induce apoptosis in THP-1 cells. Furthermore, compounds 7d and 7p were demonstrated to inhibit HDAC class I and II in THP-1 cells with comparable potency to vorinostat and increase acetylation of histones H2a, H2b, H3, and H4. Molecular modelling was used to predict the probable binding mode of the studied HDACis in class I and II histone deacetylases in terms of Zn2+ ion chelation by the hydroxamate group.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016225
003      
CZ-PrNML
005      
20250731091622.0
007      
ta
008      
250708s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ardp.202400889 $2 doi
035    __
$a (PubMed)40165669
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Onuscakova, Magdalena $u Department of Chemical Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
245    10
$a New potent N-hydroxycinnamamide-based histone deacetylase inhibitors suppress proliferation and trigger apoptosis in THP-1 leukaemia cells / $c M. Onuscakova, T. Kauerova, E. Fialova, H. Pizova, V. Garaj, M. Kemka, V. Frecer, P. Kollar, P. Bobal
520    9_
$a A new group of potent histone deacetylase inhibitors (HDACis) capable of inhibiting cell growth and affecting cell-cycle progression in Tohoku Hospital Pediatrics-1 (THP-1) monocytic leukaemia cells was synthesized. The inhibitors belong to a series of hydroxamic acid derivatives. We designed and synthesized a series of 22 N-hydroxycinnamamide derivatives, out of which 20 are new compounds. These compounds contain various substituted anilides as the surface recognition moiety (SRM), a p-hydroxycinnamate linker, and hydroxamic acids as the zinc-binding group (ZBG). The whole series of synthesized hydroxamic acids inhibited THP-1 cell proliferation. Compounds 7d and 7p, which belong to the category of derivatives with the most potent antiproliferative properties, exert a similar effect on cell-cycle progression as vorinostat and induce apoptosis in THP-1 cells. Furthermore, compounds 7d and 7p were demonstrated to inhibit HDAC class I and II in THP-1 cells with comparable potency to vorinostat and increase acetylation of histones H2a, H2b, H3, and H4. Molecular modelling was used to predict the probable binding mode of the studied HDACis in class I and II histone deacetylases in terms of Zn2+ ion chelation by the hydroxamate group.
650    _2
$a lidé $7 D006801
650    12
$a inhibitory histondeacetylas $x farmakologie $x chemická syntéza $x chemie $7 D056572
650    12
$a apoptóza $x účinky léků $7 D017209
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    12
$a protinádorové látky $x farmakologie $x chemická syntéza $x chemie $7 D000970
650    _2
$a THP-1 buňky $7 D000074084
650    _2
$a molekulární struktura $7 D015394
650    12
$a kyseliny hydroxamové $x farmakologie $x chemická syntéza $x chemie $7 D006877
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    12
$a kyseliny kumarové $x farmakologie $x chemie $x chemická syntéza $7 D003373
650    _2
$a buněčný cyklus $x účinky léků $7 D002453
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a histondeacetylasy $x metabolismus $7 D006655
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kauerova, Tereza $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000032854511X
700    1_
$a Fialova, Eva $u Department of Chemical Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
700    1_
$a Pizova, Hana $u Department of Chemical Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000279385366
700    1_
$a Garaj, Vladimir $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia
700    1_
$a Kemka, Miroslav $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia
700    1_
$a Frecer, Vladimir $u Department of Physical Chemistry of Drugs, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia $1 https://orcid.org/0000000193785860 $7 xx0331138
700    1_
$a Kollar, Peter $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000322651528 $7 xx0106036
700    1_
$a Bobal, Pavel $u Department of Chemical Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000284293810
773    0_
$w MED00000507 $t Archiv der Pharmazie $x 1521-4184 $g Roč. 358, č. 4 (2025), s. e2400889
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40165669 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091616 $b ABA008
999    __
$a ok $b bmc $g 2366813 $s 1253350
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 358 $c 4 $d e2400889 $e - $i 1521-4184 $m Archiv der Pharmazie $n Arch Pharm (Weinheim) $x MED00000507
GRA    __
$p MEYS CR infrastructure project LM2023042
GRA    __
$p Masaryk University MUNI/A/1598/2020
LZP    __
$a Pubmed-20250708
Back

Find record

Citation metrics

Archiving options